| |
Centre for Policy on Ageing | |
 | |
|
| Growth hormone, aging and frailty | | Author(s) | Finbarr C Martin, Ian Sturgess |
| Journal title | Reviews in Clinical Gerontology, vol 9, no 3, August 1999 |
| Pages | pp 207-214 |
| Keywords | Endocrine systems ; Drugs ; Biological ageing ; Research Reviews. |
| Annotation | Growth hormone (GH) decline is a widespread feature in ageing mammals, and is caused by reduced growth hormone-releasing hormone (GHRH) activity, largely resulting from a related increase in inhibition by age 55 in humans. Although there is a lack of longitudinal data, the change seems to be gradual and universal and at least partly intrinsic. Although GH has important physiological effects in adults, it is not clear that its declining secretion is responsible for somatic age-related changes in frailty or death. Nevertheless, replacement treatment has potentially worthwhile effects, but in healthy individuals, similar benefits can be obtained by exercise and nutrition without side effects. There are specific clinical situations, such as aiding recuperation after catabolic illness where therapy may have a place, particularly for frail individuals. The newer GHRPs may offer a similar and safer approach than exogenous GH. (RH). |
| Accession Number | CPA-000208213 A |
| Classmark | BKH: LLD: BH: 3A:6KC |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|